Cartas ‐ Caso clínico
Erupção psoriasiforme durante terapia com imatinibe
Yukina Watanabe
, Tomoko Hiraiwa, Mikio Ohtsuka, Toshiyuki Yamamoto
Corresponding author
Departamento de Dermatologia, Fukushima Medical University, Fukushima, Japão
Read
661
Timeswas read the article
292
Total PDF
369
Total HTML
Share statistics
array:22 [ "pii" => "S2666275224001747" "issn" => "26662752" "doi" => "10.1016/j.abdp.2024.07.019" "estado" => "S300" "fechaPublicacion" => "2024-11-01" "aid" => "1001" "copyrightAnyo" => "2024" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "Traduccion" => array:1 [ "en" => array:17 [ "pii" => "S0365059624001545" "issn" => "03650596" "doi" => "10.1016/j.abd.2023.12.006" "estado" => "S300" "fechaPublicacion" => "2024-11-01" "aid" => "1001" "documento" => "article" "crossmark" => 1 "subdocumento" => "crp" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Letter - Clinical</span>" "titulo" => "A case of psoriasiform eruption developed during imatinib therapy" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "953" "paginaFinal" => "956" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 2371 "Ancho" => 3175 "Tamanyo" => 1116399 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0005" "detalle" => "Fig. " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">(A) Psoriasiform lesions on the buttocks. (B) Similar lesions on the lower legs. (C) Histological findings revealed slight parakeratosis with a slightly flattened epidermis. Inflammatory cell infiltration was observed around blood vessels and stroma in the superficial dermis, accompanied by red blood cell extravasation. The inflammatory cells were eosinophils as well as lymphocytes and histiocytes. (Hematoxylin & eosin, ×200). (D) After treatment, the skin rash was partially improved.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Yukina Watanabe, Tomoko Hiraiwa, Mikio Ohtsuka, Toshiyuki Yamamoto" "autores" => array:4 [ 0 => array:2 [ "nombre" => "Yukina" "apellidos" => "Watanabe" ] 1 => array:2 [ "nombre" => "Tomoko" "apellidos" => "Hiraiwa" ] 2 => array:2 [ "nombre" => "Mikio" "apellidos" => "Ohtsuka" ] 3 => array:2 [ "nombre" => "Toshiyuki" "apellidos" => "Yamamoto" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "pt" => array:9 [ "pii" => "S2666275224001747" "doi" => "10.1016/j.abdp.2024.07.019" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "pt" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2666275224001747?idApp=UINPBA00008Z" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0365059624001545?idApp=UINPBA00008Z" "url" => "/03650596/0000009900000006/v1_202410230911/S0365059624001545/v1_202410230911/en/main.assets" ] ] "itemSiguiente" => array:18 [ "pii" => "S2666275224001644" "issn" => "26662752" "doi" => "10.1016/j.abdp.2024.07.009" "estado" => "S300" "fechaPublicacion" => "2024-11-01" "aid" => "991" "copyright" => "Sociedade Brasileira de Dermatologia" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "pt" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Cartas ‐ Caso clínico</span>" "titulo" => "Ictiose adquirida como precursora de linfoma gástrico difuso de grandes células B" "tienePdf" => "pt" "tieneTextoCompleto" => "pt" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "956" "paginaFinal" => "957" ] ] "contieneTextoCompleto" => array:1 [ "pt" => true ] "contienePdf" => array:1 [ "pt" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0010" "etiqueta" => "Figura 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 1258 "Ancho" => 1675 "Tamanyo" => 586685 ] ] "descripcion" => array:1 [ "pt" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Orto‐hiperceratose, ausência de camada granulosa e acantose de pequeno grau são observadas na epiderme. Na derme superior, há pequeno infiltrado linfocitário perivascular (Hematoxilina & eosina, 40<span class="elsevierStyleHsp" style=""></span>×<span class="elsevierStyleHsp" style=""></span>).</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "İrfan Yavaşoğlu, Atakan Turgutkaya, Canten Tataroğlu, Ali Zahit Bolaman" "autores" => array:4 [ 0 => array:2 [ "nombre" => "İrfan" "apellidos" => "Yavaşoğlu" ] 1 => array:2 [ "nombre" => "Atakan" "apellidos" => "Turgutkaya" ] 2 => array:2 [ "nombre" => "Canten" "apellidos" => "Tataroğlu" ] 3 => array:2 [ "nombre" => "Ali Zahit" "apellidos" => "Bolaman" ] ] ] ] ] "idiomaDefecto" => "pt" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S0365059624001442" "doi" => "10.1016/j.abd.2023.08.020" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0365059624001442?idApp=UINPBA00008Z" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2666275224001644?idApp=UINPBA00008Z" "url" => "/26662752/0000009900000006/v1_202410301154/S2666275224001644/v1_202410301154/pt/main.assets" ] "itemAnterior" => array:18 [ "pii" => "S2666275224001681" "issn" => "26662752" "doi" => "10.1016/j.abdp.2024.07.013" "estado" => "S300" "fechaPublicacion" => "2024-11-01" "aid" => "995" "copyright" => "Sociedade Brasileira de Dermatologia" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "pt" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Cartas ‐ Caso clínico</span>" "titulo" => "Caso de eritema anular eosinofílico como apresentação inicial de colangite biliar primária" "tienePdf" => "pt" "tieneTextoCompleto" => "pt" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "951" "paginaFinal" => "953" ] ] "contieneTextoCompleto" => array:1 [ "pt" => true ] "contienePdf" => array:1 [ "pt" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figura 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1677 "Ancho" => 1675 "Tamanyo" => 249209 ] ] "descripcion" => array:1 [ "pt" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">(A) Placas eritematosas anulares e arciformes com centro pigmentado nos membros inferiores. (B) Visão detalhada das lesões nas coxas.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Pablo López Sanz, Noelia de Sande Rivera, Claudia Guerrero Ramírez, Silvia Manso Córdoba, Carlota Rodríguez de Vera Guardiola, Eduardo Escario Travesedo" "autores" => array:6 [ 0 => array:2 [ "nombre" => "Pablo" "apellidos" => "López Sanz" ] 1 => array:2 [ "nombre" => "Noelia" "apellidos" => "de Sande Rivera" ] 2 => array:2 [ "nombre" => "Claudia" "apellidos" => "Guerrero Ramírez" ] 3 => array:2 [ "nombre" => "Silvia" "apellidos" => "Manso Córdoba" ] 4 => array:2 [ "nombre" => "Carlota" "apellidos" => "Rodríguez de Vera Guardiola" ] 5 => array:2 [ "nombre" => "Eduardo" "apellidos" => "Escario Travesedo" ] ] ] ] ] "idiomaDefecto" => "pt" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S036505962400148X" "doi" => "10.1016/j.abd.2023.05.014" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S036505962400148X?idApp=UINPBA00008Z" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2666275224001681?idApp=UINPBA00008Z" "url" => "/26662752/0000009900000006/v1_202410301154/S2666275224001681/v1_202410301154/pt/main.assets" ] "pt" => array:17 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Cartas ‐ Caso clínico</span>" "titulo" => "Erupção psoriasiforme durante terapia com imatinibe" "tieneTextoCompleto" => true "saludo" => "<span class="elsevierStyleItalic">Prezado Editor,</span>" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "953" "paginaFinal" => "956" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Yukina Watanabe, Tomoko Hiraiwa, Mikio Ohtsuka, Toshiyuki Yamamoto" "autores" => array:4 [ 0 => array:4 [ "nombre" => "Yukina" "apellidos" => "Watanabe" "email" => array:1 [ 0 => "yukina@fmu.ac.jp" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 1 => array:2 [ "nombre" => "Tomoko" "apellidos" => "Hiraiwa" ] 2 => array:2 [ "nombre" => "Mikio" "apellidos" => "Ohtsuka" ] 3 => array:2 [ "nombre" => "Toshiyuki" "apellidos" => "Yamamoto" ] ] "afiliaciones" => array:1 [ 0 => array:2 [ "entidad" => "Departamento de Dermatologia, Fukushima Medical University, Fukushima, Japão" "identificador" => "aff0005" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Autor para correspondência." ] ] ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figura 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 2371 "Ancho" => 3175 "Tamanyo" => 1145960 ] ] "descripcion" => array:1 [ "pt" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">(A) Aspecto clínico do paciente. Lesões psoriasiformes na região glútea. (B) Lesões semelhantes na parte inferior das pernas. (C) Histopatologia com leve paraceratose e epiderme retificada. Infiltração de células inflamatórias perivasculares na derme superficial, acompanhada de extravasamento de hemácias. As células inflamatórias eram eosinófilos, bem como linfócitos e histiócitos (Hematoxilina & eosina, 200<span class="elsevierStyleHsp" style=""></span>×<span class="elsevierStyleHsp" style=""></span>). (D) Resposta parcial ao tratamento.</p>" ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">O imatinibe é o tratamento sistêmico padrão de primeira linha para leucemia mieloide crônica e tumor estromal gastrintestinal (GIST, do inglês <span class="elsevierStyleItalic">gastrointestinal stromal tumor</span>), tendo como alvo as tirosina‐quinases BCR‐ABL e c‐KIT, respectivamente. As erupções cutâneas induzidas por imatinibe podem ser variadas, mas os casos de psoríase/erupções psoriasiformes são raros. Relata‐se aqui um desses casos juntamente com a revisão da literatura.</p><p id="par0010" class="elsevierStylePara elsevierViewall">Paciente masculino, de 69 anos, foi encaminhado ao Departamento de Dermatologia com erupção psoriasiforme. Ele havia sido tratado com imatinibe para GIST nos últimos dois anos. Dois meses após o início do tratamento com imatinibe na dose de 400<span class="elsevierStyleHsp" style=""></span>mg/dia, apareceu a erupção cutânea. O exame físico revelou pápulas vermelhas com descamação, medindo de 2 a 4<span class="elsevierStyleHsp" style=""></span>mm no tronco e membros. Além disso, na região glútea havia lesões eritêmato‐descamativas semelhantes à psoríase (<a class="elsevierStyleCrossRef" href="#fig0005">fig. 1</a>A). A biopsia de pele foi realizada em lesão eritêmato‐descamativa na perna (<a class="elsevierStyleCrossRef" href="#fig0005">fig. 1</a>B). A histopatologia revelou pequena proliferação epidérmica com paraceratose e dilatação de capilares na derme papilar, com infiltrado perivascular de células mononucleares, contendo eosinófilos (<a class="elsevierStyleCrossRef" href="#fig0005">fig. 1</a>C). O exame de sangue revelou que os eosinófilos do paciente estavam elevados entre 10% e 15%. Com base na evolução da doença, foi realizado o diagnóstico de erupção medicamentosa causada pelo imatinibe. O tratamento foi iniciado com anti‐histamínico oral e corticosteroides tópicos, e a erupção cutânea melhorou (<a class="elsevierStyleCrossRef" href="#fig0005">fig. 1</a>D). Durante o período de tratamento, o imatinibe foi continuado sem redução da dose.</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><p id="par0015" class="elsevierStylePara elsevierViewall">Reações cutâneas são os efeitos colaterais não hematológicos mais comumente relatados, ocorrendo em 9,5% a 69% dos pacientes.<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">1</span></a> Erupções maculopapulares ou eritematosas, edema e edema periorbital são comumente observados. Também foram relatadas erupções medicamentosas graves, como síndrome de Stevens‐Johnson e necrólise epidérmica tóxica. O imatinibe potencialmente afeta diretamente as células do sistema imunológico, e vários casos mostraram melhora da psoríase após a introdução do medicamento.<a class="elsevierStyleCrossRefs" href="#bib0060"><span class="elsevierStyleSup">2,3</span></a> Por outro lado, raramente foram relatados exacerbação da psoríase ou desenvolvimento <span class="elsevierStyleItalic">de novo</span> de erupção cutânea psoriasiforme. Como mecanismo patogenético, foi relatado que o tratamento com imatinibe reduziu as células T reguladoras (Tregs) CD4<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>CD25<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>FoxP3<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>e diminuiu a função imunossupressora.<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">4</span></a> Portanto, a ativação reduzida de Tregs pelo imatinibe pode contribuir para o desenvolvimento de psoríase ou erupções psoriasiformes. Também foi relatado que as erupções psoriasiformes/psoríase são, em geral, menos acentuadas, em virtude da inibição das células T efetoras pelo imatinibe.<a class="elsevierStyleCrossRef" href="#bib0060"><span class="elsevierStyleSup">2</span></a></p><p id="par0020" class="elsevierStylePara elsevierViewall">Foi realizada revisão da literatura inglesa no PubMed de 2002 a 2022, utilizando as palavras‐chave “imatinib” e “psoriasis”. Os resultados da pesquisa revelaram oito casos,<a class="elsevierStyleCrossRefs" href="#bib0060"><span class="elsevierStyleSup">2,3,5–10</span></a> cujos detalhes estão resumidos na <a class="elsevierStyleCrossRef" href="#tbl0005">tabela 1</a>. O imatinibe causou exacerbação da psoríase, início <span class="elsevierStyleItalic">de novo</span> ou mesmo melhora. A média de idade de ocorrência foi de 51,1 anos, com predomínio do gênero masculino (proporção de 6:2 homens para mulheres). O início da apresentação variou de algumas semanas a vários meses. Havia sete pacientes com psoríase preexistente, e o paciente remanescente apresentava sintomas de psoríase de início recente. Como o presente caso também foi uma erupção psoriasiforme de início recente, o caso anterior do mesmo tipo foi enfocado. Houve diferenças nos achados histopatológicos e no curso da doença. As características histopatológicas no caso anterior incluíram formação de crostas contendo neutrófilos e ausência de camada granulosa.<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">5</span></a> Por outro lado, as características histopatológicas no presente caso foram atípicas para psoríase, com pequena paraceratose, sem proliferação epidérmica evidente e ausência de microabscessos neutrofílicos subcórneos. No tratamento do paciente do caso anterior, o medicamento foi substituído,<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">5</span></a> mas o paciente do presente caso conseguiu continuar o tratamento com o imatinibe.</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0025" class="elsevierStylePara elsevierViewall">O presente relato descreveu caso raro de desenvolvimento <span class="elsevierStyleItalic">de novo</span> de erupção psoriasiforme durante tratamento com imatinibe. A erupção psoriasiforme/ psoríase induzida por imatinibe leva vários meses para se desenvolver e parece ser dependente da dose. Consequentemente, acredita‐se que esteja relacionada a efeitos farmacológicos e não com mecanismo alérgico. No presente caso, foram necessários dois meses para que a erupção se desenvolvesse. Entretanto, a erupção cutânea melhorou sem redução da dose de imatinibe. Além disso, os níveis de eosinófilos do paciente estavam elevados após o início do tratamento com imatinibe, mas melhoraram após o término do medicamento, e a infiltração de eosinófilos foi acentuada na histopatologia. Assim, sugere‐se que mecanismo alérgico ou outros efeitos farmacológicos possam estar envolvidos.</p><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0005">Suporte financeiro</span><p id="par0030" class="elsevierStylePara elsevierViewall">Nenhum.</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">Contribuição dos autores</span><p id="par0035" class="elsevierStylePara elsevierViewall">Yukina Watanabe: Aprovação da versão final do manuscrito; elaboração e redação do manuscrito.</p><p id="par0040" class="elsevierStylePara elsevierViewall">Tomoko Hiraiwa: Aprovação da versão final do manuscrito; participação intelectual em conduta propedêutica e/ou terapêutica de casos estudados.</p><p id="par0045" class="elsevierStylePara elsevierViewall">Mikio Ohtsuka: Aprovação da versão final do manuscrito; participação intelectual em conduta propedêutica e/ou terapêutica de casos estudados.</p><p id="par0050" class="elsevierStylePara elsevierViewall">Toshiyuki Ymamoto: Revisão crítica do manuscrito; aprovação da versão final do manuscrito.</p></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0015">Conflito de interesses</span><p id="par0055" class="elsevierStylePara elsevierViewall">Nenhum.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:4 [ 0 => array:2 [ "identificador" => "sec0005" "titulo" => "Suporte financeiro" ] 1 => array:2 [ "identificador" => "sec0010" "titulo" => "Contribuição dos autores" ] 2 => array:2 [ "identificador" => "sec0015" "titulo" => "Conflito de interesses" ] 3 => array:1 [ "titulo" => "Referências" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2023-10-31" "fechaAceptado" => "2023-12-08" "NotaPie" => array:2 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Como citar este artigo: Watanabe Y, Hiraiwa T, Ohtsuka M, Yamamoto T. A case of psoriasiform eruption developed during imatinib therapy. An Bras Dermatol. 2024;99:953–6.</p>" ] 1 => array:2 [ "etiqueta" => "☆☆" "nota" => "<p class="elsevierStyleNotepara" id="npar0010">Trabalho realizado na Fukushima Medical University, Fukushima, Japão.</p>" ] ] "multimedia" => array:2 [ 0 => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figura 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 2371 "Ancho" => 3175 "Tamanyo" => 1145960 ] ] "descripcion" => array:1 [ "pt" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">(A) Aspecto clínico do paciente. Lesões psoriasiformes na região glútea. (B) Lesões semelhantes na parte inferior das pernas. (C) Histopatologia com leve paraceratose e epiderme retificada. Infiltração de células inflamatórias perivasculares na derme superficial, acompanhada de extravasamento de hemácias. As células inflamatórias eram eosinófilos, bem como linfócitos e histiócitos (Hematoxilina & eosina, 200<span class="elsevierStyleHsp" style=""></span>×<span class="elsevierStyleHsp" style=""></span>). (D) Resposta parcial ao tratamento.</p>" ] ] 1 => array:8 [ "identificador" => "tbl0005" "etiqueta" => "Tabela 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at1" "detalle" => "Tabela " "rol" => "short" ] ] "tabla" => array:1 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Idade, gênero \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Dose de imatinibe \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Erupção \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">História de psoríase \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Duração \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Terapia \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Resultado do tratamento \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1<a class="elsevierStyleCrossRef" href="#bib0080"><span class="elsevierStyleSup">6</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">52, M \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">400 mg/dia \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Exacerbação \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2 meses \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Corticosteroide tópico, pomada de calcipotriol, retomada de imatinibe 200 mg/dia \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Melhorou \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2<a class="elsevierStyleCrossRef" href="#bib0085"><span class="elsevierStyleSup">7</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">55, M \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">400 mg/dia \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Exacerbação \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2 meses \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Corticosteroides tópicos e análogos da vitamina D, tratamento continuado com imatinibe \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Persistiu \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2<a class="elsevierStyleCrossRef" href="#bib0090"><span class="elsevierStyleSup">8</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">62, F \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">400 mg/dia \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Exacerbação \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">4 semanas \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Descontinuação de imatinibe, retomada de imatinibe 400 mg/dia, metotrexato 12,5 mg/semana \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Melhorou \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3<a class="elsevierStyleCrossRef" href="#bib0095"><span class="elsevierStyleSup">9</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">63, M \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">400 mg/dia \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Exacerbação \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3 semanas \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Descontinuação, UVB de banda estreita \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Melhorou \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">4<a class="elsevierStyleCrossRef" href="#bib0100"><span class="elsevierStyleSup">10</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">57, M \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">400 mg/dia \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Exacerbação \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Desconhecida \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Descontinuação, retomada de imatinibe 200 mg/dia, pomada de vitamina D3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Melhorou \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">5<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">5</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">21, M \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">400 mg/dia \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Início <span class="elsevierStyleItalic">de novo</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>−<span class="elsevierStyleHsp" style=""></span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">5 meses \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Descontinuação, UVB de banda estreita \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Melhorou \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">6<a class="elsevierStyleCrossRef" href="#bib0060"><span class="elsevierStyleSup">2</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">35, M \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">400 mg/dia \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Melhora \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 mês \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Desconhecida \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Não descrito \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">7<a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">3</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">64, M \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">400 mg/dia \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Melhora \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2 semanas \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Não descrita \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Não descrito \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Presente caso \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">69, M \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">400 mg/dia \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Início <span class="elsevierStyleItalic">de novo</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>−<span class="elsevierStyleHsp" style=""></span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2 meses \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Redução do imatinibe para 300 mg/dia, corticosteroide tópico \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Melhorou \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab3706864.png" ] ] ] ] "descripcion" => array:1 [ "pt" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Casos de psoríase associados a imatinibe</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "Referências" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:10 [ 0 => array:3 [ "identificador" => "bib0055" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Lichenoid drug eruption related to imatinib: report of a new case and review of the literature" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "E. Sendagorta" 1 => "P. Herranz" 2 => "M. Feito" 3 => "P. Ramírez" 4 => "R. Feltes" 5 => "U. Floristán" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2230.2009.03266.x" "Revista" => array:6 [ "tituloSerie" => "Clin Exp Dermatol." "fecha" => "2009" "volumen" => "34" "paginaInicial" => "e315" "paginaFinal" => "e316" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19456782" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0060" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Imatinib induced complete remission of psoriasis in a patient with chronic myeloid leukemia" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "A. Jain" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Indian J Hematol Blood Transfus." "fecha" => "2020" "volumen" => "36" "paginaInicial" => "198" "paginaFinal" => "199" ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0065" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Improvement of psoriasis during imatinib therapy in a patient with a metastatic gastrointestinal stromal tumour" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "S. Miyagawa" 1 => "H. Fujimoto" 2 => "S. Ko" 3 => "S. Hirota" 4 => "Y. Kitamura" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1046/j.1365-2133.2002.497217.x" "Revista" => array:6 [ "tituloSerie" => "Br J Dermatol." "fecha" => "2002" "volumen" => "147" "paginaInicial" => "406" "paginaFinal" => "407" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12174137" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0070" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Imatinib mysylate inhibits CD4<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>CD25<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>regulatory T‐cell activity and enhances active immunotherapy against BCR‐ABL‐ tumors" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "N. Larmonier" 1 => "N. Janikashvili" 2 => "C.J. LaCasse" 3 => "C.B. Larmonier" 4 => "J. Cantrell" 5 => "E. Situ" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Immunol." "fecha" => "2008" "volumen" => "181" "paginaInicial" => "6955" "paginaFinal" => "6963" ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0075" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Imatinib‐induced psoriasis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "F. Atalay" 1 => "E. Kızılkılıç" 2 => "R.S. Ada" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.4274/Tjh.2012.0147" "Revista" => array:6 [ "tituloSerie" => "Turk J Haematol." "fecha" => "2013" "volumen" => "30" "paginaInicial" => "216" "paginaFinal" => "218" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24385791" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0080" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Exacerbation of psoriasis after imatinib mesylate treatment" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.H. Shim" 1 => "S.H. Oh" 2 => "J.Y. Jun" 3 => "J.H. Kim" 4 => "H.Y. Park" 5 => "J.H. Park" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.5021/ad.2016.28.3.409" "Revista" => array:6 [ "tituloSerie" => "Ann Dermatol." "fecha" => "2016" "volumen" => "28" "paginaInicial" => "409" "paginaFinal" => "411" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27274651" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0085" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Imatinib: a designer drug, another cutaneous complication" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "E. Dickens" 1 => "F. Lewis" 2 => "N. Bienz" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2230.2009.03250.x" "Revista" => array:6 [ "tituloSerie" => "Clin Exp Dermatol." "fecha" => "2009" "volumen" => "34" "paginaInicial" => "603" "paginaFinal" => "604" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19486036" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0090" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Management of imatinib‐related exacerbation of psoriasis in a patient with a gastrointestinal stromal tumour" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "H. Cheng" 1 => "D.E. Geist" 2 => "M. Piperdi" 3 => "R. Virk" 4 => "B. Piperdi" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1440-0960.2008.00495.x" "Revista" => array:6 [ "tituloSerie" => "Australas J Dermatol." "fecha" => "2009" "volumen" => "50" "paginaInicial" => "41" "paginaFinal" => "43" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19178491" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0095" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Exacerbation of psoriasis in a chronic myelogenous leukemia patient treated with imatinib" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "S.M. Woo" 1 => "C.H. Huh" 2 => "K.C. Park" 3 => "S.W. Youn" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1346-8138.2007.00369.x" "Revista" => array:6 [ "tituloSerie" => "J Dermatol." "fecha" => "2007" "volumen" => "34" "paginaInicial" => "724" "paginaFinal" => "726" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17908148" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0100" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Psoriasis vulgaris exacerbated by imatinib therapy in chronic myelogenous leukemia" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "K. Shimizu" 1 => "H. Kuroda" 2 => "M. Kida" 3 => "H. Watanabe" 4 => "S. Shirao" 5 => "T. Akiyama" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Rinsho Ketsueki." "fecha" => "2005" "volumen" => "46" "paginaInicial" => "1152" "paginaFinal" => "1155" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16440780" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "pt" "url" => "/26662752/0000009900000006/v1_202410301154/S2666275224001747/v1_202410301154/pt/main.assets" "Apartado" => array:4 [ "identificador" => "95145" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Cartas - Caso Clínico" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/26662752/0000009900000006/v1_202410301154/S2666275224001747/v1_202410301154/pt/main.pdf?idApp=UINPBA00008Z&text.app=https://clinics.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2666275224001747?idApp=UINPBA00008Z" ]
Article information
ISSN: 26662752Original language: Portuguese
The statistics are updated each day
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 18 | 8 | 26 |
| 2024 October | 181 | 92 | 273 |
| 2024 September | 170 | 192 | 362 |
